Cell Biotech Co

Cell Biotech Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 11.89. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 0.75 — a change of 1,493.64% (higher).

EV/EBITDA

11.89

YoY

1,493.64%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Cell Biotech Co is 2025 11.89 . EV/EBITDA (Enterprise Value to EBITDA) of Cell Biotech Co was 2024 0.75 . It decreases by 1,493.64% higher compared to the previous year.

The Cell Biotech Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
1.42 KRW
Jan 1, 2019
4.79 KRW
Jan 1, 2020
6.52 KRW
Jan 1, 2021
3.75 KRW
Jan 1, 2022
3.38 KRW
Jan 1, 2023
5.17 KRW
Jan 1, 2024
0.75 KRW
Jan 1, 2025
11.89 KRW
The Cell Biotech Co EV/EBITDA history
YEAREV/EBITDAYoY
11.89+1,493.64%
0.75-85.58%
5.17+52.96%
3.38-9.86%
3.75-42.42%
6.52+36.09%
4.79+237.54%
1.42-3.97%
1.48-14.64%
1.73-36.30%
2.72-61.71%
7.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Cell Biotech Co is 11.89 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Cell Biotech Co changed from 0.75 to 11.89, representing a 1,493.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cell Biotech Co

All Key Metrics — Cell Biotech Co